Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

BACKGROUND: Pembrolizumab alone or in combination with chemotherapy is a standard treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression. However, no study has compared the efficacies of these two regimens. Therefore, we aimed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Hiromi, Kobayashi, Nobuaki, Somekawa, Kohei, Fukuda, Nobuhiko, Kaneko, Ayami, Kamimaki, Chisato, Kubo, Sousuke, Tanaka, Katsushi, Tagami, Yoichi, Teranishi, Shuhei, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Koizumi, Harumi, Miura, Kenji, Miyazawa, Naoki, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758435/
https://www.ncbi.nlm.nih.gov/pubmed/34866339
http://dx.doi.org/10.1111/1759-7714.14252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758435/
https://www.ncbi.nlm.nih.gov/pubmed/34866339
http://dx.doi.org/10.1111/1759-7714.14252

Ejemplares similares